LFG
IOVA icon

Larson Financial Group’s Iovance Biotherapeutics IOVA Stock Holding History

Larson Financial Group’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-1,000
Closed -$14.8K – 2461
2024
Q1 		$14.8K Buy
+1,000
New +$11.6K ﹤0.01% 956
2023
Q4 		– Sell
-1,200
Closed -$5.46K – 1859
2023
Q3 		$5.46K Hold
1,200
– – ﹤0.01% 1147
2023
Q2 		$8.45K Hold
1,200
– – ﹤0.01% 984
2023
Q1 		$7.33K Hold
1,200
– – ﹤0.01% 1001
2022
Q4 		$7.67K Hold
1,200
– – ﹤0.01% 936
2022
Q3 		$11K Hold
1,200
– – ﹤0.01% 771
2022
Q2 		$13K Hold
1,200
– – ﹤0.01% 639
2022
Q1 		$20K Buy
+1,200
New +$18.6K ﹤0.01% 525
2021
Q4 		– Sell
-800
Closed -$20K – 1124
2021
Q3 		$20K Hold
800
– – ﹤0.01% 467
2021
Q2 		$21K Hold
800
– – ﹤0.01% 428
2021
Q1 		$25K Hold
800
– – 0.01% 370
2020
Q4 		$37K Hold
800
– – 0.01% 256
2020
Q3 		$26K Buy
+800
New +$24.5K 0.01% 278

Other funds holding IOVA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
MFM
MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

Larson Financial Group's IOVA Position: Q2 2024 in Review

Larson Financial Group sold out of Iovance Biotherapeutics (IOVA) in Q2 2024, closing a stake of 1,000 shares — an estimated $14.8K sold.

Larson Financial Group first reported a position in IOVA in Q3 2020 and held it in 13 quarters. The position peaked at $37K in Q4 2020. 295 funds tracked by Wall St. Rank hold IOVA as of Q2 2024.

  • Larson Financial Group reported no remaining Iovance Biotherapeutics position as of Q2 2024 after selling out during the quarter.
  • Larson Financial Group sold 1,000 Iovance Biotherapeutics shares in Q2 2024, an estimated $14.8K.
  • Larson Financial Group first reported a position in Iovance Biotherapeutics in Q3 2020 and held it in 13 quarters.
  • Larson Financial Group's Iovance Biotherapeutics position peaked at $37K in Q4 2020.
  • 295 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q2 2024.

Based on Larson Financial Group's 13F filing for Q2 2024, filed 2 Aug 2024.